Skip to main content

Arch Biopartners Inc(ARCH-X)
TSX Venture

Today's Change
Delayed Last Update

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

Globe Newswire - Tue Jan 4, 2022

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that the Research Ethics Board at the Sunnybrook Research Institue has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide (LSALT and “Metablok”) in a new arm of the CATCO human trial. CATCO leadership will now seek Health Canada approval before commencing the dosing of LSALT in the new arm of the trial.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.